Chronic Pain Clinical Trial
Official title:
Immunologic Response to Negative Cognition in Persons With Chronic Pain
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future
Leaders in Pain Small Research Grants Application Page 5 Continuation Format Page
Summary: Chronic pain is stressful, both physically and psychologically. Stressful
experiences induce autonomic nervous system arousal, which reliably leads to inflammation and
immune suppression. Inflammation then exacerbates existing pain and may be a key factor in
both the genesis and maintenance of pain. Stress-induced immune effects are detected two
hours (2 hrs) post-stressor, suggesting only a few stressful experiences per day may be
sufficient to sustain elevated pain levels1. Cognition has emerged as a potential mediating
factor in the relationship between pain and stress. Mentally recreating an emotionally
stressful event induces de novo physiological stress1. In other words, thinking about an
emotionally charged event down-regulates autonomic stress responses and subsequent immune
effects. Therefore, exploring cognition as a mediating factor between stress, pain, and
inflammation will inform our understanding of pain pathways, as well as improve treatment for
pain.
Study Rationale: The acute stress response induces immunosuppression; however, this
relationship has been studied in arbitrary models only (shock avoidance, job interview). This
study employs the novel approach of examining stress and immune responses to a personally
relevant stressor (pain); prior studies used arbitrary models only (shock avoidance, job
interview). Pain offers a highly salient and personal context well-suited for investigation
of negative cognitive perseveration. Pain is acutely sensitive to exacerbation via
inflammation, and thus the relevance of examining immune effects of rumination on future
negative expectations ("expecting the worst") is underscored.
Goal: To test the biological consequences of negative expectations, achieved via an active
10-minute negative cognitive perseveration on a personally relevant stressor: future
worsening of one's chronic pain condition. Biological stress response will be measured via
heart rate (HR), blood pressure (BP) and serum cortisol. Impact of negative cognition on
inflammation will be measured using interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor
necrosis factor-alpha (TNF-α) as biomarkers of immune function, controlling for depression
and pain catastrophizing. This study aims to inform the understanding of pain mechanisms.
Aim 1: Determine the magnitude of an autonomic stress response to an induction of negative
cognition.
Aim 2: Determine immune effects of the experiment-induced stress response.
Aim 3: Establish whether a pre-existing tendency to catastrophize mediates the relationship
between experiment-induced negative perseveration and immune effects.
Aim 4: Establish whether stress-related increases in IL-6 remain elevated post 2 hrs.
Methods: This prospective study examines the magnitude of biological stress and subsequent
immunologic changes in response to negative cognitive perseveration. Five physiological
measurement time points occur over the course of the 3 hour experiment.
Demographics and health characteristics of interest: gender, marital status, smoking status,
education level, race, height, weight, body mass index, medical comorbidity, psychological
comorbidity, medications (for inflammation, pain, or psychiatric conditions).
Inclusionary Criteria
- >18 years of age; <65 years of age
- Non-inflammatory musculoskeletal patients presenting for evaluation at Oregon Health &
Science University (OHSU) Comprehensive Pain Center (CPC)
Exclusionary Criteria
- Active or recent virus/infection
- Thought disorder, Suicidality,
- Substance Abuse
- Active corticosteroid regimen
- Pregnancy
- Limited venous access
- Former intravenous drug user
Enrollment: All persons presenting for evaluation at the CPC who meet study criteria will be
offered the option to participate in the study. Approximately 60 new pain patients are
evaluated by psychology monthly and we expect to obtain our goal of 40 participants within 6
months. Informed consent will be obtained in compliance with OHSU Institutional Review Board
protocol. Subjects will receive $100 gift certificate compensation, even if they fail to
complete the study. We anticipate a low completion failure rate as the study is completed in
one 3-hour time block. Study times will be standardized to account for circadian effects.
Participants will be told to arrive having eaten a light breakfast with minimal caffeine
consumption (e.g., less than 2 cups of coffee). They will be given a subject number and their
psychiatric diagnoses will be blinded to prevent bias. The study involves gathering 5 serum
samples and thus participants will be catheterized by nursing staff to minimize physiological
stress.
Principal Investigator/Program Director (Last, First, Middle): Darnall, Beth APS Future
Leaders in Pain Small Research Grants Application Page 7 Continuation Format Page
Study site: The study will be conducted at the NIH-funded General Clinical Research Center
(GCRC). The GCRC provides state of the art resources including research space, specialized
research nurses to perform blood draws and gather biodata, biostatisticians, and
sophisticated laboratories to perform serum biomarker analysis. OHSU's GCRC is Oregon's
premier multidisciplinary patient-oriented research facility and is housed in the same
building as the CPC, thus minimizing travel burden on participants.
Active Stress Induction: Negative Cognitive Perseveration On their experiment day,
participants will interface with a licensed clinical psychologist who did not perform their
clinical interview and who is blinded to their diagnoses. The psychologist will instruct the
participant talk for 10 minutes about the worst aspects of their pain, to discuss their loss
of control over their situation, the negative impact pain has had on their life and others.
They will be guided to imagine that their situation will progressively worsen, and to focus
on how badly they will feel as a result. Two measures of induction efficacy will be given:
subjective verbal rating (0-10) and objective rating by attending psychologist (0-10). The
intervention ends at 10 minutes and the remainder of the study involves biodata measurement.
Study ends at 2.5 hrs post induction following the final blood draw. The psychologist will
debrief subjects and will assess their affective state. Their subjective units of distress
will be checked. Persons who are in a continued negative cognitive state will receive 30
minutes of Cognitive Behavioral Therapy (CBT) by the on-site psychologist. Care will be taken
not to allow participants to leave the study site in distress. Participants will receive
follow up psychology care at the CPC as indicated in their treatment plan.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
| Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
| Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
| Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
| Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
| Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
| Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
| Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
| Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
| Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
| Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
| Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
| Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
| Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
| Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
| Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
| Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
| Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
| Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|